Communiqués Dogwood Therapeutics, Inc.

Actions

DWTX

US92829J2033

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 21/08/2026			Varia. 5j.	Varia. 1 janv.
2,490 ^USD	+6,87%		+15,81%	-40,14%

13/08	Dogwood Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
20/07	Dogwood Therapeutics, Inc. recrute les 200 premiers patients pour son essai de phase 2b Halneuron sur la neuropathie induite par la chimiothérapie	CI

Communiqués

18/08	Dogwood to Host Virtual KOL Event to Discuss Halneuron for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026	AQ
17/08	Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026	AQ
13/08	Dogwood Therapeutics Announces Second Quarter 2026 Financial Results	AQ
20/07	Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026	AQ
30/06	Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board	AQ
18/05	Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study	AQ
14/05	Dogwood Therapeutics Announces First Quarter 2026 Financial Results	AQ
13/05	Dogwood Therapeutics : Corporate Presentation (Dogwood Non Confidential Corporate Update May 2026)	PU
12/05	Dogwood Therapeutics : Corporate Presentation (Dogwood Therapeutics Non Confidential Corporate Update May 2026)	PU
07/05	Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026	AQ
23/04	Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M	AQ
15/04	Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy	AQ
26/03	Dogwood Therapeutics : Shareholder Letter March 2026	PU
18/03	Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results	AQ
02/02	Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026	AQ
26/01	Dogwood Therapeutics : Corporate Presentation (Dogwood Therapeutics Non Confidential Corporate Update Q1 2026)	PU
20/01	Dogwood Therapeutics : Shareholder Letter January 2026	PU
12/01	Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development	AQ
22/12	Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain	AQ
02/12	Dogwood Therapeutics : Files New Synthetic Halneuron(R) Intellectual Property Protection Projected to Extend Exclusivity Period Up to 2045	PU
12/11	Dogwood Announces Enrollment of First 100 Patients in Ongoing Halneuron Phase 2b Trial, Interim Sample Size Analysis on Track for December 2025	AQ
06/11	Dogwood Therapeutics Reports Third Quarter 2025 Financial Results	AQ
31/10/25	Dogwood Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025	AQ
27/10/25	Dogwood Therapeutics : Corporate Presentation (Dogwood Therapeutics Q4 2025 Corporate Update10.15.25 )	PU
09/10/25	Dogwood Therapeutics : Corporate Presentation (Dogwood Therapeutics Q4 2025 Corporate Update )	PU